Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics.

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid increasing demand for GLP-1 therapy.

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale ...

SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and other drugs, the CDMO’s investment plan is paying off big time.

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year partnership with CordenPharma, a leading contract manufacturing firm.

Viking Therapeutics shares rocketed to an all-time high last February after the company announced positive clinical trial results for its weight-management candidate, VK2735.